Cumberland Pharmaceuticals (CPIX) & The Competition Critical Review

Cumberland Pharmaceuticals (NASDAQ: CPIX) is one of 636 publicly-traded companies in the “DRUGS” industry, but how does it weigh in compared to its peers? We will compare Cumberland Pharmaceuticals to similar businesses based on the strength of its institutional ownership, earnings, analyst recommendations, valuation, profitability, dividends and risk.

Risk and Volatility

How to Become a New Pot Stock Millionaire

Cumberland Pharmaceuticals has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals’ peers have a beta of 0.30, suggesting that their average stock price is 70% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Cumberland Pharmaceuticals and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cumberland Pharmaceuticals 0 0 0 0 N/A
Cumberland Pharmaceuticals Competitors 3229 10232 26106 737 2.60

As a group, “DRUGS” companies have a potential upside of 41.45%. Given Cumberland Pharmaceuticals’ peers higher possible upside, analysts plainly believe Cumberland Pharmaceuticals has less favorable growth aspects than its peers.

Institutional & Insider Ownership

34.7% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 46.5% of shares of all “DRUGS” companies are held by institutional investors. 38.0% of Cumberland Pharmaceuticals shares are held by company insiders. Comparatively, 16.1% of shares of all “DRUGS” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Cumberland Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cumberland Pharmaceuticals -19.39% -1.55% -1.14%
Cumberland Pharmaceuticals Competitors -3,656.99% -134.43% -29.59%

Valuation & Earnings

This table compares Cumberland Pharmaceuticals and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Cumberland Pharmaceuticals $41.15 million -$7.97 million -13.38
Cumberland Pharmaceuticals Competitors $1.79 billion $140.83 million -7.01

Cumberland Pharmaceuticals’ peers have higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Cumberland Pharmaceuticals beats its peers on 5 of the 9 factors compared.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc. (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company’s product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease; Vaprisol (conivaptan) Injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Hepatoren (ifetroban) Injection, and Boxaban (ifetroban) oral capsules for the treatment of patients with aspirin-exacerbated respiratory disease (AERD).

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Atlantic Capital  Receiving Somewhat Favorable Press Coverage, Accern Reports
Atlantic Capital Receiving Somewhat Favorable Press Coverage, Accern Reports
Foresight Energy  Receives Daily Media Sentiment Rating of -0.02
Foresight Energy Receives Daily Media Sentiment Rating of -0.02
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Park-Ohio  Stock Price
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Park-Ohio Stock Price
Ribbon Communications Inc  Receives $7.56 Consensus PT from Analysts
Ribbon Communications Inc Receives $7.56 Consensus PT from Analysts
Analysts Set Progressive Co.  Price Target at $53.43
Analysts Set Progressive Co. Price Target at $53.43
Brokerages Set Fortune Brands Home & Security  Target Price at $73.62
Brokerages Set Fortune Brands Home & Security Target Price at $73.62


© 2006-2018 Ticker Report. Google+.